UNSPSC 51334400: Antipsychotics, synthesized

This classification denotes Antipsychotics composed of multiple constituents, with no dominant constituent.

UNSPSC 51334400 Antipsychotics, synthesized (Class) does not align with the state and local procurement activity currently tagged under it. The recent opportunities on record—a Seminole County naloxone and drug deactivation systems purchase, a Texas HHS Request for Information on direct-to-manufacturer pharmacy contracts, and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products—center on drug procurement, pharmacy benefit program management, and emergency response pharmaceuticals, not antipsychotic medications specifically. State and local issuing bodies pursuing pharmaceutical procurement include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances that serve state agencies and local governments across multiple jurisdictions.

The geographic footprint spans Florida (Seminole County), Texas (HHS Commission), and Minnesota with broader multi-state reach through MMCAP, which includes Oregon among participating members. The most recent opportunities are Seminole County's IFB 60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2023 (noting a date inconsistency in the source); Texas HHS's RFI HHS0017013 for direct-to-manufacturer prescription program capabilities posted April 3, 2026; and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products due March 26, 2026, with awards effective July 1, 2026. Interested vendors should verify whether antipsychotic-specific procurement exists under this code or whether the code assignment reflects a data taxonomy mismatch rather than genuine demand signal for antipsychotic formulations in state and local contracting.